Thyrocare Technologies has announced its audited financial results for the quarter and financial year ended March 31, 2026. The company reported a significant increase in annual revenue to ₹774.27 crore on a standalone basis, compared to ₹633.10 crore in the previous year. Profit after tax for the fiscal year rose to ₹148.81 crore, reflecting solid operational growth. The Board has also recommended a final dividend of ₹7 per equity share.
Standalone Financial Performance
For the financial year ended March 31, 2026, Thyrocare Technologies achieved a revenue from operations of ₹774.27 crore, a robust improvement from ₹633.10 crore in FY2025. The profit for the year reached ₹148.81 crore, up from ₹95.78 crore in the previous year. For the fourth quarter (January-March 2026), the company reported revenue of ₹210.67 crore and a profit of ₹43.58 crore.
Consolidated Results and Business Segments
On a consolidated basis, the Group performed strongly, reporting an annual revenue of ₹829.04 crore for FY2026, compared to ₹687.35 crore in FY2025. The consolidated profit attributable to owners of the company for the year stood at ₹163.05 crore.
The company operates primarily through two segments: Diagnostic Testing Services and Imaging Services. The Diagnostic Testing segment remains the primary driver, contributing ₹772.53 crore to the annual consolidated revenue, while the Imaging Services segment contributed ₹53.14 crore.
Strategic Updates and Dividend
The Board of Directors has recommended a final dividend of ₹7 per equity share (face value of ₹10 each) for the financial year ended March 31, 2026, subject to approval by shareholders. Additionally, the company noted that it has successfully navigated regulatory changes, including the implementation of new labour codes, which were managed as exceptional items. The company continues to maintain a strong focus on core diagnostic operations and the growth of its subsidiary, Nueclear Healthcare Limited.
Source: BSE
